Manufacture of aseptic, purified, cryopreserved Plasmodium vivax sporozoites

无菌、纯化、冷冻保存的间日疟原虫子孢子的制造

基本信息

  • 批准号:
    10011236
  • 负责人:
  • 金额:
    $ 99.9万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2016
  • 资助国家:
    美国
  • 起止时间:
    2016-04-21 至 2023-05-31
  • 项目状态:
    已结题

项目摘要

ABSTRACT Malaria caused by Plasmodium vivax (Pv) parasites is ranked second with respect to the incidence and severity of disease while Plasmodium falciparum (Pf) malaria is ranked first. However unlike Pf, chemo prophylactic measures against Pv do not prevent relapses, unique to Pv, that occur due to re-activation of persistent liver-stage sleeping forms of the parasites called hypnozoites. Primaquine is the only licensed drug that targets Pv hypnozoites, but it causes life threatening acute hemolytic anemia in patients with G6PD deficiency, the most prevalent human genetic disorder, affecting 8% of people in malaria-endemic nations. Efforts to develop better drugs or produce a much needed vaccine are further hampered by the inability to propagate blood stages of Pv parasites in vitro, unlike Pf. Therefore generating infected mosquitoes for controlled human malaria infection (CHMI) as a means to assess anti-Pv drugs and vaccines, is entirely reliant on feeding of mosquitoes on fresh, Pv-infected blood from patients with Pv malaria. Together, these bottlenecks make the task of developing and testing robust interventions against Pv malaria more challenging compared to Pf. We have made significant progress under a phase I grant toward establishing and maintaining a colony of specific pathogen free (SPF) Saimiri boliviensis (Sb). and vialing aseptic, purified Plasmodium vivax (Pv) sporozoites (SPZ) that were generated in aseptic mosquitoes using infected blood from SPF Sb and met asepticity and release criteria in all in process and for release. We now outline phase 2 follow-up plans to manufacture a lot of PvSPZ Challenge in compliance with cGMPs, conduct quality control release and stability studies, prepare a clinical trial protocol, and prepare and submit an Investigational New Drug (IND) application to the FDA along with an infectivity study in humanized FRG KO huHEP mice, and an immunogenicity and protective efficacy study in a mouse model with patent parasitemia as the protection outcome. The product resulting from studies outlined in this proposal will be called Sanaria® PvSPZ Challenge, and similar to PfSPZ Challenge will provide the larger malaria community with a tool to assess the efficacy of drugs and vaccines against Pv malaria with a safer quality-controlled reagent that exhibits minimal variability in potency between different lots, is logistically more feasible to administer, and is not subject to geographical limitations for application, compared to traditional CHMI using mosquito bites. It will represent an unprecedented milestone in the field of vaccinology, and vaccine manufacturing and most importantly it will form the basis of a powerful vaccine approach to preventing Pv malaria when administered with anti-malarial chemoprophylaxis, the PvSPZ chemoprophylaxis vaccine (PvSPZ-CVac).
摘要 由间日疟原虫(Pv)寄生虫引起的疟疾在发病率方面排名第二, 疾病的严重程度,而恶性疟原虫(Pf)疟疾排名第一。然而,与Pf不同,化疗 针对Pv的预防措施不能预防Pv特有的复发,复发是由于Pv的重新激活而发生的。 被称为催眠虫的寄生虫的持续性肝脏阶段睡眠形式。伯氨喹是唯一一种 靶向Pv催眠虫,但在G6 PD患者中可引起危及生命的急性溶血性贫血 缺乏症是最普遍的人类遗传性疾病,影响了疟疾流行国家8%的人。 开发更好的药物或生产急需的疫苗的努力进一步受到阻碍, 在体外繁殖Pv寄生虫的血液阶段,不像Pf。 控制人类疟疾感染(CHMI)作为评估抗Pv药物和疫苗的一种手段, 用Pv疟疾患者的新鲜的、被Pv感染的血液喂养蚊子。所有这些 瓶颈使得开发和测试针对Pv疟疾的强有力干预措施的任务更具挑战性 我们在第一阶段赠款下取得了重大进展, 无特定病原体(SPF)的玻利维亚塞米里鱼(Sb)的菌落。和瓶装的无菌纯化疟原虫 使用来自SPF Sb的感染血液在无菌蚊子中产生间日疟原虫(Pv)子孢子(SPZ), 所有过程中和放行均符合无菌性和放行标准。我们现在概述第二阶段的后续计划, 按照cGMP生产大量PvSPZ挑战品,进行质量控制放行和稳定性 研究,准备临床试验方案,并准备和提交研究性新药(IND)申请 沿着在人源化FRG KO huHEP小鼠中的感染性研究,以及免疫原性和 在小鼠模型中进行的保护功效研究,以寄生虫血症作为保护结果。产品 本提案中概述的研究结果将被称为Sanaria® PvSPZ挑战,与PfSPZ相似 挑战将为更大的疟疾社区提供评估药物和疫苗效力的工具 使用更安全的质量控制试剂对抗Pv疟疾, 不同的地段,在后勤上更可行的管理,并不受地理限制, 与使用蚊子叮咬的传统CHMI相比,这将是一个前所未有的里程碑, 疫苗学和疫苗制造领域,最重要的是,它将构成强大的基础 预防Pv疟疾的一种疫苗方法,即PvSPZ 化学预防疫苗(PvSPZ-CVac)。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

STEPHEN Lev HOFFMAN其他文献

STEPHEN Lev HOFFMAN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('STEPHEN Lev HOFFMAN', 18)}}的其他基金

Modularizing manufacture of PfSPZ vaccines: ookinete production for PfSPZ manufacture in mosquitoes and in vitro
PfSPZ 疫苗的模块化生产:在蚊子和体外生产 PfSPZ 的动合生产
  • 批准号:
    10761373
  • 财政年份:
    2023
  • 资助金额:
    $ 99.9万
  • 项目类别:
Progressing PfSPZ vaccines for malaria to licensure and commercialization
推进 PfSPZ 疟疾疫苗的许可和商业化
  • 批准号:
    10602357
  • 财政年份:
    2023
  • 资助金额:
    $ 99.9万
  • 项目类别:
PfSPZ Vaccine for Prevention of Plasmodium falciparum malaria
用于预防恶性疟原虫疟疾的 PfSPZ 疫苗
  • 批准号:
    10406059
  • 财政年份:
    2022
  • 资助金额:
    $ 99.9万
  • 项目类别:
Attenuation of Liquid Formulation for PfSPZ Vaccine by X-Ray
X 射线法测定 PfSPZ 疫苗液体制剂的减毒效果
  • 批准号:
    10156019
  • 财政年份:
    2021
  • 资助金额:
    $ 99.9万
  • 项目类别:
Attenuation of Liquid Formulation for PfSPZ Vaccine by X-Ray
X 射线法测定 PfSPZ 疫苗液体制剂的减毒效果
  • 批准号:
    10391482
  • 财政年份:
    2021
  • 资助金额:
    $ 99.9万
  • 项目类别:
Development of Non-Human Primate Models to Assess Immunological Mechanisms and Antigenic Targets of Protective Sporozoite (SPZ) Vaccines and Establish Superior Efficacy of Next Generation SPZ vaccines
开发非人灵长类动物模型来评估保护性子孢子 (SPZ) 疫苗的免疫机制和抗原靶点并确定下一代 SPZ 疫苗的卓越功效
  • 批准号:
    10381696
  • 财政年份:
    2021
  • 资助金额:
    $ 99.9万
  • 项目类别:
Development of Non-Human Primate Models to Assess Immunological Mechanisms and Antigenic Targets of Protective Sporozoite (SPZ) Vaccines and Establish Superior Efficacy of Next Generation SPZ vaccines
开发非人灵长类动物模型来评估保护性子孢子 (SPZ) 疫苗的免疫机制和抗原靶点并确定下一代 SPZ 疫苗的卓越功效
  • 批准号:
    10598147
  • 财政年份:
    2021
  • 资助金额:
    $ 99.9万
  • 项目类别:
Enhancement of gametocytogenesis in Plasmodium falciparum by genetic engineering for improved PfSPZ Vaccine Manufacture
通过基因工程增强恶性疟原虫配子细胞发生以改进 PfSPZ 疫苗生产
  • 批准号:
    10082070
  • 财政年份:
    2020
  • 资助金额:
    $ 99.9万
  • 项目类别:
Enhancement of gametocytogenesis in Plasmodium falciparum by genetic engineering for improved PfSPZ Vaccine Manufacture
通过基因工程增强恶性疟原虫配子细胞发生以改进 PfSPZ 疫苗生产
  • 批准号:
    10239239
  • 财政年份:
    2020
  • 资助金额:
    $ 99.9万
  • 项目类别:
Manufacture of aseptic, purified, cryopreserved Plasmodium vivax sporozoites (PvSPZ Challenge) for controlled human malaria infection (CHMI)
生产无菌、纯化、冷冻保存的间日疟原虫子孢子(PvSPZ Challenge)用于控制人类疟疾感染(CHMI)
  • 批准号:
    9265783
  • 财政年份:
    2016
  • 资助金额:
    $ 99.9万
  • 项目类别:

相似海外基金

Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 99.9万
  • 项目类别:
    Fellowship
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 99.9万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 99.9万
  • 项目类别:
    Collaborative R&D
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 99.9万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 99.9万
  • 项目类别:
    Standard Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 99.9万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 99.9万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 99.9万
  • 项目类别:
    Research Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 99.9万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Collaborative Research: Changes and Impact of Right Ventricle Viscoelasticity Under Acute Stress and Chronic Pulmonary Hypertension
合作研究:急性应激和慢性肺动脉高压下右心室粘弹性的变化和影响
  • 批准号:
    2244994
  • 财政年份:
    2023
  • 资助金额:
    $ 99.9万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了